Allergan plc (AGN)
(Delayed Data from NYSE)
$145.81 USD
+1.56 (1.08%)
Updated May 3, 2019 04:01 PM ET
After-Market: $145.88 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$145.81 USD
+1.56 (1.08%)
Updated May 3, 2019 04:01 PM ET
After-Market: $145.88 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Allergan (AGN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Allergan (AGN) closed at $166.70 in the latest trading session, marking a +0.15% move from the prior day.
Will Patent Woes Boost Pharma Stock Megamergers Further?
by Nilanjan Banerjee
With key drugs losing exclusivity, key drug makers are poised to face deep trouble since their sales are mostly dependent on a single drug.
Intra-Cellular Therapies' Candidate Fails in Phase III Study
by Zacks Equity Research
Intra-Cellular Therapies' (ITCI) lead candidate fails to meet primary endpoint in one of the phase III studies evaluating it in bipolar depression patients. Shares fall.
AbbVie (ABBV) Shares Down So Far This Year: Here's Why
by Zacks Equity Research
AbbVie's (ABBV) stock suffers a poor run on the bourses due to pipeline setbacks, Humira sales erosion in EU and its proposed offer to buy Allergan.
Editas (EDIT) Focuses on Developing Eye Candidate EDIT-101
by Zacks Equity Research
Editas (EDIT) focuses on the development of its lead candidate, EDIT-101, for treating LCA10, a rare genetic illness that causes blindness. Excessive reliance on partners for revenues remains a woe.
Allergan (AGN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Allergan (AGN) closed at $169.61, marking a +0.04% move from the previous day.
Can Allergan (AGN) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Allergan (AGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will the Pharma Space Witness More Mega-Merger Deals in 2H?
by Kinjel Shah
After two mega-mergers, Bristol-Myers/Celgene and AbbVie/Allergan, in first half of 2019, it remains to be seen if more such deals are in store for the second half.
Email API Platforms Gather Steam: VG, TWLO and AMZN in View
by Madhura Bhattacharyya
Let's take a look at how Vonage (VG), Twilio (TWLO) and Amazon (AMZN) are incorporating email to address the growing needs and preferences of customers in the cloud communications market.
Pharma Stock Roundup: ABBV to Buy AGN, BMY to Sell CELG's Otezla to Close Merger
by Kinjel Shah
AbbVie (ABBV) announces definitive deal to buy Allergan (AGN). Bristol-Myers (BMY) set to sell Celgene's Otezla to complete the impending merger.
Is Allergan a Good Deal for AbbVie?
by Sejuti Banerjea
AbbVie is dishing out $63 billion in stock and cash for Allergan, provided it gets regulatory approval.
AbbVie to Buy Allergan: Prescribed ETFs
by Sweta Killa
AbbVie has agreed to buy Botox-maker Allergan for $63 billion in a cash-and-stock deal. The news has put the spotlight on a number of healthcare ETFs.
Company News For Jun 26, 2019
by Zacks Equity Research
Companies in the news are: ABBV, AGN, LEN, XNCR, USNA and LION
AbbVie to Acquire Allergan in Nearly $62B Cash & Stock Deal
by Zacks Equity Research
AbbVie (ABBV) offers nearly $63 billion to acquire Botox-maker Allergan to diversify its product portfolio.
The Zacks Analyst Blog Highlights: AbbVie, Allergan, Bristol-Myers and Celgene
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AbbVie, Allergan, Bristol-Myers and Celgene
Axsome Initiates Phase III Study on Depression Candidate
by Zacks Equity Research
Axsome (AXSM) initiates phase III GEMINI study of AXS-05 for the treatment of major depressive disorder.
AbbVie + Allergan: Where Are The Synergies?
by Daniel Laboe
AbbVie (ABBV) is on the hunt for their next big revenue driver as their patent for the world???s top-selling drug, Humira, is nearing its end. AbbVie just made a $63 billion deal to acquire Dublin-based Allergan (AGN) in an attempt to keep their drive alive.
AbbVie (ABBV) Stock Falls After $63 Billion Allergan Acquisition Announcement
by Zachary Stutler
AbbVie announced Tuesday morning its intent to acquire Allergan for $63 billion.
Abbvie Decides to Acquire Allergan
by Zacks Equity Research
Abbvie Decides to Acquire Allergan
AbbVie to Buy Botox-Maker Allergan, Look Ahead to G-20
by Mark Vickery
AbbVie (ABBV) has agreed to purchase Botox maker Allergan (AGN) for roughly $63 billion in cash and stock.
Allergan's Botox Wins FDA Nod for Upper Limb Spasticity in Kids
by Zacks Equity Research
Allergan's (AGN) Botox gets FDA approval for the 10th therapeutic indication, upper limb spasticity in pediatric patients, in the age group of 2 to 17 years.
Allergan (AGN) in Focus: Stock Moves 6.2% Higher
by Zacks Equity Research
Allergan (AGN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
The Zacks Analyst Blog Highlights: Amgen, Alexion, Regeneron, Allergan and Savara
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amgen, Alexion, Regeneron, Allergan and Savara
Company News For Jun 20, 2019
by Zacks Equity Research
Companies In The News Are: VIAB,CBS,ADBE,X,AGN,IRWD
Allergan Up As Analyst Statement Sparks Business Split Rumors
by Zacks Equity Research
Allergan's (AGN) shares up following a conference call with one of the company's executives, which led an analyst to believe that a split of the company's business is in the cards.